Enzolytics IncOTC Pink - Current Information:ENZC
- LAST PRICE0.0010
- TODAY'S CHANGE (%)0.0001 (11.1111%)
- Bid / Lots0.0010/ 9,694
- Ask / Lots0.0011/ 24,644
- Open / Previous Close0.0011 / 0.0009
- Day Range
- 52 Week Range
- Volume3,960,288
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENZC |
|---|---|---|
| 09:32 ET | 64276 | 0.001 |
| 09:37 ET | 5000 | 0.001 |
| 09:44 ET | 10000 | 0.00095 |
| 09:48 ET | 700000 | 0.001 |
| 09:53 ET | 1500 | 0.001 |
| 10:04 ET | 54200 | 0.0011 |
| 10:06 ET | 15500 | 0.00104 |
| 10:08 ET | 1500 | 0.001035 |
| 10:22 ET | 10553 | 0.001 |
| 10:24 ET | 100 | 0.001 |
| 10:27 ET | 100000 | 0.001 |
| 10:33 ET | 673 | 0.00104 |
| 10:38 ET | 345262 | 0.00105 |
| 10:40 ET | 5000 | 0.001 |
| 10:42 ET | 15000 | 0.00105 |
| 10:44 ET | 30000 | 0.001 |
| 10:45 ET | 30000 | 0.001 |
| 10:47 ET | 2110000 | 0.001 |
| 10:51 ET | 5000 | 0.001 |
| 11:03 ET | 39900 | 0.001 |
| 11:12 ET | 110000 | 0.0011 |
| 11:23 ET | 1500 | 0.001 |
| 11:32 ET | 1892 | 0.00105 |
| 11:34 ET | 3400 | 0.001 |
| 11:36 ET | 275000 | 0.001 |
| 11:52 ET | 20000 | 0.001 |
| 11:54 ET | 5000 | 0.001 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enzolytics Inc | 3.5M | 0.0x | --- |
Dogwood Therapeutics Inc | 3.6M | -0.5x | --- |
ProtoKinetix Inc | 3.5M | -8.8x | --- |
Synaptogenix Inc | 3.5M | -0.3x | --- |
NuCana PLC | 2.9M | 0.0x | --- |
Lixte Biotechnology Holdings Inc | 3.4M | -0.9x | --- |
Company Information
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).
Contact Information
- Headquarters
- 120 W Pomona AveMONROVIA, CA, United States 91016
- Phone
- 626-538-4779
- Fax
- 845-818-3588
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.9B |
Enzolytics Inc does not pay a dividend. | |
Beta | 0.86 |
EPS | $-0.11 |
Book Value | $-0.96 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
